ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models

• Published in: International journal of molecular sciences Vol. 22; no. 1; p. 241
• Main Authors: Yeom, Dong-Hoon, Lee, Yo-Seob, Ryu, Ilhwan, Lee, Sunju, Sung, Byungje, Lee, Han-Byul, Kim, Dongin, Ahn, Jin-Hyung, Ha, Eunsin, Choi, Yong-Soo, Lee, Sang Hoon, You, Weon-Kyoo
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 29-12-2020; MDPI
• Subjects: Adaptor Proteins, Signal Transducing - antagonists & inhibitors; Angiogenesis; Animals; anti-angiogenesis; Antiangiogenics; Antibodies; Antibodies, Bispecific - pharmacology; Antibodies, Bispecific - therapeutic use; Apoptosis; Apoptosis - drug effects; Biological activity; Bispecific antibodies; Calcium-Binding Proteins - antagonists & inhibitors; Cancer therapies; Cell Line, Tumor; Chemotherapy; Colon; Colon cancer; Colorectal cancer; delta-like ligand; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; FDA approval; Humans; Irinotecan; Mice; Monoclonal antibodies; Neovascularization, Pathologic - drug therapy; Niacinamide - analogs & derivatives; Niacinamide - pharmacology; Niacinamide - therapeutic use; Paclitaxel; Patients; Pyrazoles - pharmacology; Pyrazoles - therapeutic use; therapeutic antibody; Tumors; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Vascular endothelial growth factor receptors; VEGF; Xenograft Model Antitumor Assays; Xenografts; Xenotransplantation; therapeutic antibody; paclitaxel; irinotecan; delta-like ligand; VEGF; anti-angiogenesis
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms22010241

Delta-like-ligand 4 (DLL4) is a promising target to augment the effects of VEGF inhibitors. A simultaneous blockade of VEGF/VEGFR and DLL4/Notch signaling pathways leads to more potent anti-cancer effects by synergistic anti-angiogenic mechanisms in xenograft models. A bispecific antibody targeting VEGF and DLL4 (ABL001/NOV1501/TR009) demonstrates more potent in vitro and in vivo biological activity compared to VEGF or DLL4 targeting monoclonal antibodies alone and is currently being evaluated in a phase 1 clinical study of heavy chemotherapy or targeted therapy pre-treated cancer patients (ClinicalTrials.gov Identifier: NCT03292783). However, the effects of a combination of ABL001 and chemotherapy on tumor vessels and tumors are not known. Hence, the effects of ABL001, with or without paclitaxel and irinotecan were evaluated in human gastric or colon cancer xenograft models. The combination treatment synergistically inhibited tumor progression compared to each monotherapy. More tumor vessel regression and apoptotic tumor cell induction were observed in tumors treated with the combination therapy, which might be due to tumor vessel normalization. Overall, these findings suggest that the combination therapy of ABL001 with paclitaxel or irinotecan would be a better clinical strategy for the treatment of cancer patients.